iZafe Group AB Series B Total Liabilities
iZafe Group AB Series B total liabilities. Based on the latest financial reports, iZafe Group AB Series B (IZAFE-B) has total liabilities worth Skr26.10 Million SEK (≈ $2.81 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check iZafe Group AB Series B (IZAFE-B) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of iZafe Group AB Series B (2010–2025)
Total liabilities of iZafe Group AB Series B from 2010 to 2025. This chart illustrates how iZafe Group AB Series B's total liabilities have evolved over time, based on quarterly financial data.
iZafe Group AB Series B Competitors by Total Liabilities
The table below lists competitors of iZafe Group AB Series B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FSBM Holdings Bhd
KLSE:9377
|
Malaysia | RM5.93 Million |
|
Rewardle Holdings Ltd
AU:RXH
|
Australia | AU$10.12 Million |
|
Asuransi Dayin Mitra Tbk
JK:ASDM
|
Indonesia | Rp389.61 Billion |
|
Concord Medical Services Holdings
NYSE:CCM
|
USA | $4.70 Billion |
|
Ihlas Ev Aletleri Imalat Sanayi ve Ticaret AS
IS:IHEVA
|
Turkey | TL943.19 Million |
|
Guideline Geo AB (publ)
ST:GGEO
|
Sweden | Skr34.35 Million |
|
Lovable Lingerie Limited
NSE:LOVABLE
|
India | Rs173.66 Million |
|
ShreeOswal Seeds And Chemicals Limited
NSE:OSWALSEEDS
|
India | Rs895.11 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down iZafe Group AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IZAFE-B current and non-current assets.
Liquidity & Leverage Metrics
iZafe Group AB Series B Total Liabilities Ratios Explained
iZafe Group AB Series B total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how iZafe Group AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for iZafe Group AB Series B (2010–2025)
The table below shows the annual total liabilities of iZafe Group AB Series B from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr23.95 Million ≈ $2.58 Million |
+65.15% |
| 2024-12-31 | Skr14.50 Million ≈ $1.56 Million |
+56.59% |
| 2023-12-31 | Skr9.26 Million ≈ $996.63K |
-21.12% |
| 2022-12-31 | Skr11.74 Million ≈ $1.26 Million |
+52.55% |
| 2021-12-31 | Skr7.70 Million ≈ $828.21K |
+36.89% |
| 2020-12-31 | Skr5.62 Million ≈ $605.02K |
-83.87% |
| 2019-12-31 | Skr34.86 Million ≈ $3.75 Million |
+4.17% |
| 2018-12-31 | Skr33.46 Million ≈ $3.60 Million |
+1224.22% |
| 2017-12-31 | Skr2.53 Million ≈ $271.95K |
-5.55% |
| 2016-12-31 | Skr2.68 Million ≈ $287.93K |
-27.63% |
| 2015-12-31 | Skr3.70 Million ≈ $397.87K |
-39.01% |
| 2014-12-31 | Skr6.06 Million ≈ $652.40K |
+11.88% |
| 2013-12-31 | Skr5.42 Million ≈ $583.10K |
+4.52% |
| 2012-12-31 | Skr5.18 Million ≈ $557.91K |
+993.60% |
| 2011-12-31 | Skr474.05K ≈ $51.02K |
-40.66% |
| 2010-12-31 | Skr798.87K ≈ $85.97K |
-- |
About iZafe Group AB Series B
iZafe Group AB (publ), a medical technology company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated medication dispenser that handles medication pouches, smart pillboxes, facilitates and enables independent medication, and reminds and alerts in the scheduled doses. It also o… Read more